Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice

European Journal of Pharmacology

Volumn 465, Issue 1-2, 2003, Pages 43-52

  Cuadrado, Antonio ^a   Bravo, Jesús ^a   Armijo, Juan A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

4 Aminopyridine; Drug interaction; Felbamate; Lamotrigine; Pentylenetetrazole

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOPYRIDINE; FELBAMATE; GLUTAMIC ACID; LAMOTRIGINE; PENTETRAZOLE;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG POTENTIATION; LABORATORY TEST; MALE; MONOTHERAPY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

EID: 0037470754     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01460-2     Document Type: Article

References (48)

1. Arzimanoglou A., Kulak I., Bidaut-Mazel C., Baldy-Moulinier M. Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy. Rev. Neurol. 157:2001;525-536.
2. Bourgeois B.F.D. Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J. Pharmacol. Exp. Ther. 247:1988;1128-1132.
3. Bourgeois B.F.D. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin. Neuropharmacol. 11:1988;348-359.
4. Brodie M.J., Yuen A.W.C. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 26:1997;423-432.
5. Chez M.G., Bourgeois B.F.D., Pippenger C.E., Knowles W.D. Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice. Clin. Neuropharmacol. 17:1994;32-37.
6. Cilio M.R., Kartashov A.I., Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res. 47:2001;1-7.
7. Colucci R., Glue P., Holt B., Banfield C., Reidenberg P., Meenan J.W., Pai S., Nomeir A., Lim J., Lin C.-C., Affrime M.B. Effect of felbamate on the pharmacokinetics of lamotrigine. J. Clin. Pharmacol. 36:1996;634-638.
8. Cramer C.L., Stagnitto M.L., Knowles M.A., Palmer G.C. Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci. 54:1994;271-275.
9. Cuadrado A., De las Cuevas I., Valdizán E.M., Armijo J.A. Synergistic interaction between valproate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. Eur. J. Pharmacol. 453:2002;43-52.
10. Czuczwar S.J., Przesmycki K. Felbamate, gabapentin and topiramate as adjuvant antiepileptic drugs in experimental models of epilepsy. Pol. J. Pharmacol. 53:2001;65-68.
11. Davis R., Peters D.H., McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47:1994;332-372.
12. De Sarro G., Nava F., Aguglia U., De Sarro A. Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Neuropharmacology. 35:1996;153-158.
13. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 46:1957;208-209.
14. Fariello R.G., Varasi M., Smith M.C. Valproic acid: mechanisms of action. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;581-588 Raven Press, New York, NY.
15. Ferrie C.D., Panayiotopoulus C.P. Therapeutic interactions of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure. 3:1994;157-159.
16. Ferrie C.D., Robinson R.O., Knott C., Panayiotopoulos C.P. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand. 91:1995;200-202.
17. Fraser A.D., MacNeil W., Isner A.F., Camfield P.R. Lamotrigine analysis in serum by high-performance liquid chromatography. Ther. Drug Monit. 17:1995;174-178.
18. Fraser C.M., Sills G.J., Forrest G., Thompson G.G., Brodie M.J. Neurochemical studies with the anticonvulsant felbamate in mouse brain. Pharmacol. Res. 40:1999;257-261.
19. French J., Smith M., Faught E., Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Neurology. 52:1999;1540-1545.
20. Frey H.H., Bartels I. Felbamate and meprobamate: a comparison of their anticonvulsant properties. Epilepsy Res. 27:1997;151-164.
21. Gordon R., Gels M., Wichmann J.K., Diamantis W., Sofia R.D. Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Epilepsia. 34:1993;367-371.
22. Lamb R.J., Miller A.A. Effect of lamotrigine and some known anticonvulsant drugs on visually-evoked after-discharge in the conscious rat. Br. J. Pharmacol. 86:1985;765P. (Abstract).
23. Leach J.P. Polypharmacy with anticonvulsants: focus on synergism. CNS Drugs. 8:1997;366-375.
24. Leach J.P., Sills G.J., Butler E., Forrest G., Thompson G.G., Brodie M.J. Neurochemical actions of gabapentin in mouse brain. Epilepsy Res. 27:1997;175-180.
25. Levy R.H., Bourgeois B.F.D. Drug-drug interactions. Engel J. Jr., Pedley T.A. Epilepsy: A Comprehensive Textbook. 1997;1175-1179 Lippincott-Raven, Philadelphia.
26. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
27. Löscher W., Fassbender C.P., Gram L., Gramer M., Hörstermann D., Zahner B., Stefan H. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res. 14:1993;245-255.
28. Macdonald R.L. Cellular actions of antiepileptic drugs. Eadie M.J., Vajda F.J.E. Antiepileptic Drugs. Pharmacology and Therapeutics. 1999;123-149 Springer-Verlag, Berlin.
29. McCabe P.H., Michel N.C., McNew C.D. Clinical efficacy of combination therapy with valproic acid and lamotrigine in intractable epilepsy: high success rate with low incidence of rash. Epilepsia. 39:1998;49. (Abstract).
30. McCabe P.H., McNew C.D., Michel N.C. Effect of divalproex-lamotrigine combination therapy in frontal lobe seizures. Arch. Neurol. 58:2001;1264-1268.
31. Meldrum B.S., Leach M. The mechanism of action of lamotrigine. Rev. Contemp. Pharmacother. 5:1994;107-114.
32. Miller A.A., Wheatley P., Sawyer D.A., Baxter M.G., Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia. 27:1986;483-489.
33. Panayiotopoulos G.P., Ferrie C.D., Knott C., Robinson R.O. Interaction of lamotrigine with sodium valproate. Lancet. 341:1993;445. (Letter).
34. Pellock J.M. Felbamate. Epilepsia. 40(Suppl. 5):1999;S57-S62.
35. Pisani F., Di Perri R., Perucca E., Richens A. Interaction of lamotrigine with sodium valproate. Lancet. 341:1993;1224. (Letter).
36. Pisani F., Oteri G., Russo M.F., Di Perri R., Perucca E., Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 40:1999;1141-1146.
37. Privitera M., Welty T.E. Lamotrigine combined with valproate for idiopathic generalized epilepsy. Epilepsia. 39:1998;52. (Abstract).
38. Rowan A.J., Meijer J.W.A., de Beer-Pawlikowski N., van der Geest P., Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch. Neurol. 40:1983;797-802.
39. Sayin Ü., Cengiz S., Altug T. Vigabatrin as an anticonvulsant against pentylenetetrazole seizures. Pharmacol. Res. 28:1993;325-331.
40. Smith S.E., al-Zubaidy Z.A., Chapman A.G., Meldrum B.S. Excitatory amino acids, lamotrigine and BW 1003C87 as anticonvulsants in genetically epilepsy-prone rat. Epilepsy Res. 15:1993;101-111.
41. Sofia R.D. Felbamate: mechanisms of action. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;791-797 Raven Press, New York, NY.
42. Swinyard E.A., Sofia R.D., Kupferberg H.J. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia. 27:1986;27-34.
43. Turnell D.C., Cooper J.D.H. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clin. Chem. 28:1982;527-531.
44. Valdizán E.M., Armijo J.A. Effects of single and multiple increasing doses of vigabatrin on brain GABA metabolism and correlation with vigabatrin plasma concentration. Biochem. Pharmacol. 43:1992;2143-2150.
45. Waldmeier P.C., Martin P., Stocklin K., Portet C., Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;154-162.
46. Wheatley P.L., Miller A.A. Effects of lamotrigine on electrically induced afterdischarge duration in anaesthetised rat, dog, and marmoset. Epilepsia. 30:1989;34-40.
47. White H.S., Wolf H.H., Woodhead J.H., Kupferberg H.J. The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy. French J., Leppik I., Dichter M.A. Antiepileptic Drug Development. Advances in Neurology. vol. 76:1998;29-39 Lippincott-Raven, Philadelphia.
48. Yamaguchi S., Rogawski M.A. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res. 11:1992;9-16.